This message is sent to you by FDA Newswatch

Regulatory Inspections and Quality Audits

Tuesday, 31 March 2020 10:00 AM PDT | 01:00 PM EDT

Training Duration = 90 min              Sponsored by ComplianceOnline

Click Here to register $249.00

Click Here to register and receive CD recording $429.00

This course will focus on Regulatory Inspections and Quality Audits. It will cover Health Authority inspections as well as internal Quality Audits and also managing corrective action plans that can result from audits.

Why Should You Attend:

Regulatory Inspections and Quality Audits are something every Pharmaceutical and Biotech company should be familiar with. These can be inspections conducted by Health Authorities, such as the US Food and Drug Administration, or they can be audits the company does internally to either prepare for a Health Authority inspection, or just to ensure proper operations at their manufacturing sites. This course will cover the basics for both of these types of inspections and audits, including giving companies basics to be prepared for both the inspection/audit and the outcomes.

  • Gain a better understanding of Inspections by Health Authorities
  • Better understand reasons for conducting internal voluntary audits
  • Understand the importance of Health Authority Communications with regard to Inspections
  • Understand the roles of Regulatory, Quality Assurance, CMC and Manufacturing play in Inspections and Audits
  • Better understand the outcomes of Inspections and Audits and what companies next steps should be in dealing with them

Areas Covered in the Webinar:

  • FDA Audits/Inspections
  • Other Health Authority Audits
  • Pre-Inspection/Audit Preparation
  • Internal Roles during an Inspection/Audit
  • Dealing with the aftermath of Health Authority Inspections
  • The 483 Form
  • Internal Audit results and how to handle them
  • Reporting requirements for internal audits

Instructor Profile:

Martin A. Lessem, J.D. is a professional with 17 years of experience in Pharmaceuticals. In the past 12 years he has been heavily involved with Regulatory Risk Management and worked on many of the larger industry programs.

He has worked at large companies, small companies, innovator companies, and generic companies and has worked in risk management in all those settings. Currently, he is a consultant to Pharmaceutical companies on Regulatory Strategy and Risk Management.